The sum was factored into the company’s sales and earnings outlook for the year, he said. Meanwhile, Pfizer expanded its ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer’s pipeline is robust, with RSV vaccine expansions and AI-driven R&D enhancing long-term prospects. Cost-cutting measures, including manufacturing optimization, improved adjusted gross ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its ...

Pfizer on Tuesday reaffirmed its outlook for ... The company launched its multiyear cost-cutting plan in 2023 after the drugmaker miscalculated demand for its Covid-19 products.